| Leptospirosis Getting an Early Start this Year | | Posted Friday, January 05, 2007 2:55:50 PM by Blog57 Team | | Erin Ryder Researchers at the University of Kentucky's Livestock Disease Diagnostic Center have reported numerous early cases of leptospirosis, a bacterial disease that can cause a variety of equine problems, including abortion, a flu-like illness, and uveitis (moon blindness). Leptospirosis can spread from horses to humans. Craig Carter, DVM PhD, a professor of epidemiology at the university, said the center has seen 10 cases of leptospirosis in Kentucky since October, compared to zero cases in the same timeframe last year. With the upcoming Kentucky breeding and foaling season closing in, Carter said he believes there will be many more leptospirosis cases. "It feels like we're maybe shifting a little earlier, maybe a couple of months, of when we see cases," Carter said.... | |
| |
| | | EyeGate Pharma Secures $10M in Series B Venture Funding | | Posted Friday, November 10, 2006 1:01:46 PM by Blog57 Team | | WALTHAM, MA and PARIS -- (MARKET WIRE) -- November 02, 2006 -- EyeGate Pharma, a specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced that it has secured a Series B venture round of funding totaling $10 million led by Innoven Partenaires and co-led by Ventech, both of Paris, France. This brings the total venture investment in the Company to $14M. The Company plans to keep this round open for potential U.S. venture firms interested in becoming part of the syndicate. The financing allows EyeGate Pharma to bring its clinical candidates for severe uveitis and glaucoma into the clinic in 2007 using its proprietary EyeGate® II Delivery System. The announcement will be made today by President and CEO Stephen From in a presentation at the Massachusetts Biotechnology Council's MASS Opportunities Investor Conference being held in Boston at the Hilton Logan Airport Hotel.... | |
| |
| | | EyeGate Pharma Starts U.S. Operations in Waltham, MA | | Posted Thursday, November 09, 2006 7:04:20 AM by Blog57 Team | | EyeGate Pharma, a specialty pharmaceutical company pioneering the use of iontophoresis technology to safely deliver therapeutics for ocular indications, today announced the start of its U.S. operations at 100 Beaver Street, Waltham, MA in 12,200 square feet of combined office and lab space. The Company also formally introduced its President & CEO, Stephen From, a former Chief Financial Officer and life science investment banker, as well as other key members of its senior management team. EyeGate Pharma, a privately held, venture-backed specialty pharmaceutical company, is using its proprietary iontophoretic technology to safely and non-invasively deliver therapeutics to the anterior and posterior chambers of the eye. Thomas M. Finneran, President, Massachusetts Biotechnology Council, commented on the news, "Massachusetts welcomes EyeGate to our expanding community of world-class life science companies.... | |
| |
| | | Circadian IOP-Lowering Efficacy of Travoprost 0.004% Ophthalmic Solution Compared to Latanoprost 0.005%* | | Posted Thursday, October 26, 2006 2:54:00 AM by Blog57 Team | | By Garca-Feijoo, J; Martnez-de-la-Casa, J M; Castillo, A; Mndez, C; Et al Key words: Glaucoma - Intraocular pressure - Latanoprost - Ocular hypertension - Prostaglandin - Travoprost ABSTRACT Purpose: The primary objective of this study was to determine the intraocular pressure- (IOP) lowering efficacy over two consecutive 24-h periods of travoprost 0.004% ophthalmic solution (Travatan[dagger]) compared to latanoprost 0.005% (Xalatan[double dagger]) dosed once daily in patients with primary open-angle glaucoma or ocular hypertension. Methods: This was a double-masked trial conducted at the Hospital Clnico San Carlos, Madrid, Spain. The primary objective of this study was to determine the IOP lowering efficacy of travoprost and latanoprost.... | |
| |
| | | Lux Biosciences Establishes European-Based Operations | | Posted Thursday, October 05, 2006 10:54:11 PM by Blog57 Team | | Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, today announced that it has established Lux Biosciences GmbH in Frankfurt, Germany as a wholly owned subsidiary with the mission to create the infrastructure for the company's European activities. By developing a product pipeline in the US and Europe simultaneously, Lux intends to create significant synergies in drug and market development. In addition, this effort builds on Lux's recent milestones, including the following: "Our European activities are an integral part of Lux's overarching strategy to develop a product pipeline with the broadest practical scope, which for us includes North America and Europe," said Ulrich Grau, Ph.D., president and chief executive officer of Lux Biosciences.... | |
| |
| | | pSivida Appoints Non-Executive Director to Audit Committee | | Posted Tuesday, October 03, 2006 12:54:17 PM by Blog57 Team | | BOSTON & PERTH, Australia, Sept. 26, 2006--(BUSINESS WIRE)--Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced the appointment of Stephen Lake to the Company’s audit committee effective as of September 20, 2006. Mr. Lake has been a member of the Company’s board of directors since July 30, 2004. .... | |
| |
| | | Vishwa Samvada Kendra: | | Posted Friday, September 29, 2006 6:54:23 AM by Blog57 Team | | Dialogue on Media and Hindutva, K N Shanth Kumar, Editor, Deccan Herald and Prajavani, journalists S Gurumurthy, Saeed Naqvi, A Suryaprakash, Tarun Vijay, A Jayaram, Chandanmitra, Vishveshwara Bhat, academicians N S Ashok Kumar and Varadesh Hiregange participate, Hotel Woodlands, Raja Ram Mohan Roy Road, near Richmond Circle, 10 am. .... | |
| |
| | | A Novel, Preservative-Free Steroid Formulation for Use as an Anti-Inflammatory | | Posted Friday, September 22, 2006 2:54:46 AM by Blog57 Team | | Corticosteroids, such as dexamethasone, methylprednisolone and triamcinolone acetonide (TAC), have been used for many years in the treatment of inflammation and in relieving pain caused by inflammation (for example chronic back and joint pain). Intraocular inflammation is also treated with steroids; however, there are no commercial corticosteroid preparations approved by the FDA for use in the eye and off-label use of current commercial formulations can be accompanied by toxic side effects, which can lead to vision loss. Inflammation is present in eye diseases including uveitis, diabetic retinopathy, venous occlusive disease and age-related macular degeneration, which are estimated to affect more than 200,000 patients in the U.S. alone. This number is likely to increase as the population ages, and there remains a need for a cost-effective, safe, efficient steroid formulation for treating these conditions.... | |
| |
| | | TOO OLD T O O S O O N Research and in the case of a Redwood City girl, inspiration and a lot of loving care raise | | Posted Friday, September 15, 2006 6:56:27 AM by Blog57 Team | | BERNADETTE and Mark Gersh first noticed something wasn't quite right with their 15-month old daughter Jordan in October 2000. As they wandered through a Half Moon Bay pumpkin patch, the Redwood City parents watched children close to Jordan's age running and playing around the pumpkins. Meanwhile, Jordan was barely able to stand on her own. At first it hadn't worried them that Jordan wasn't walking yet ? they figured she was just slow to start. But once they saw her among other children, their daughter's inability to fully straighten her legs and stand by herself became cause for concern. "It wasn't until she was amidst other kids that it struck us that something might be wrong. We took her to see her pediatrician and she was sent to see a neurologist and orthopedic doctor, but nothing came up," says Bernadette Gersh.... | |
| |
| | | FDA Expands Remicade® (Infliximab) Psoriatic Arthritis Indication ... | | Posted Saturday, September 09, 2006 4:59:53 AM by Blog57 Team | | Centocor, Inc., announced that the U.S. Food and Drug Administration (FDA) has extended its approval for REMICADE (infliximab) for inhibiting progression of structural damage and improving physical function in patients with psoriatic arthritis, in addition to reducing signs and symptoms of active arthritis. The approval is based on one-year data from the double-blind, placebo-controlled trial IMPACT 2 and two-year data from the double-blind, placebo-controlled trial IMPACT. Findings from IMPACT 2 showed that at week 24, patients treated with REMICADE had less structural damage as assessed radiographically compared with patients receiving placebo (mean change -0.70 vs. 0.82, P About IMPACT/IMPACT 2 The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) was a Phase 2b randomized, double-blind, placebo-controlled study that involved 104 patients with active psoriatic arthritis (defined as affecting at least five joints) who failed at least one DMARD.... | |
| |
| |
|
|
